《中国医药科学》杂志欢迎您的投稿!.   今天是:        
何彩红,朱水染.α-硫辛酸联合依帕司他与硫辛酸单用对糖尿病神经源性膀胱的疗效观察[J].中国医药科学,19,(14):24-27        基金项目:
α-硫辛酸联合依帕司他与硫辛酸单用对糖尿病神经源性膀胱的疗效观察
Therapeutic effect of α-lipoic acid combined with epalrestat and α-lipoic acid in the treatment of diabetic neurogenic bladder
  
DOI:
中文关键词:  糖尿病;神经源性膀胱;α- 硫辛酸;依帕司他;膀胱功能
英文关键词:Diabetes mellitus; Neurogenic bladder; α-lipoic acid; Epalrestat; Bladder function
作者单位
何彩红,朱水染 广东省吴川市人民医院内分泌科,广东吴川 524500 
摘要点击次数: 414
全文下载次数: 911
中文摘要:
      目的 研究比较 α- 硫辛酸联合依帕司他与单用 α- 硫辛酸治疗糖尿病神经源性膀胱的临床疗效。 方法 选取于我院就医的 98 例糖尿病合并神经源性膀胱患者(2016 年 1 月~ 2018 年 7 月)进行前瞻性研究,采用随机数字表法将患者分为两组,各 49 例,对照组单用 α- 硫辛酸治疗,观察组给予 α- 硫辛酸 + 依帕司他治疗,比较两组的临床疗效、膀胱功能指标、氧化应激指标、生活质量评分、不良反应发生率。 结果(1)组间临床疗效比较,观察组的总有效率高于对照组(P < 0.05)。(2)两组治疗后的残余尿量、逼尿肌压力、最大尿流率均较治疗前改善(P < 0.05),而在治疗后,观察组的残余尿量、逼尿肌压力均小于对照组(P< 0.05),其最大尿流率大于对照组(P < 0.05)。(3)两组治疗后的 SOD、MDA、AOPP 均较治疗前改善(P < 0.05),而在治疗后,观察组的 SOD 高于对照组(P < 0.05),其 MDA、AOPP 均低于对照组(P < 0.05)。(4)两组治疗后的生活质量各项评分均较治疗前增高(P < 0.05),而治疗后观察组的生活质量各项评分均高于对照组(P < 0.05)。(5)观察组、对照组的不良反应总发生率分别为 6.12%、2.04%,比较差异无统计学意义(P > 0.05)。 结论 α- 硫辛酸与依帕司他联合用于糖尿病合并神经源性膀胱患者中,可有效改善患者膀胱功能,抑制其氧化应激反应,有利于提高患者的临床疗效,使其生活质量改善,且安全性良好,不会增加不良反应。
英文摘要:
      Objective To compare the clinical efficacy of α-lipoic acid combined with epalcitrate and α-lipoic acid in the treatment of diabetic neurogenic bladder. Methods 98 diabetic patients with neurogenic bladder (from January 2016 to July 2018) in our hospitalwas selected andprospectively analyzed. The patients were divided into two groups by random number table method, each had 49 cases. The control group was treated with single α -lipoic acid, the observation group was treated with α-lipoic acid and epalcitrate, the clinical efficacy, bladder function index, oxidative stress index, quality of life scores and adverse reaction rate were compared between the two groups. Results(1) The total effective rate of the observation group was higher than the control group (P < 0.05). (2)After treatment, compared withbefore treatment, the residual urine volume, detrusor pressure and maximum urineflow rate of the two groupswere improved(P < 0.05), while the residual urine volume and detrusor pressure of the observation group were lower than the control group (P < 0.05), and the maximum urine flow rate was higher thanthe control group (P < 0.05).(3) SOD, MDA and AOPP in both groups were improved after treatment (P < 0.05), while SOD in the observation group was higher than the control group (P < 0.05), and MDA and AOPPwere lower than the control group (P < 0.05). (4) The quality of life scores of the two groups after treatment were higher than those before treatment (P < 0.05), while the quality of life scores of the observation group after treatment were higher than the control group (P < 0.05). (5) The total incidence of adverse reactions in the observation group and the control group was 6.12% and 2.04%, respectively, with no statistical difference (P > 0.05). Conclusion α-lipoic acid combined with epalcitratein the treatment of diabetic neurogenic bladder can effectively improve the bladder function, inhibit the oxidative stress response, improve the clinical efficacy and the quality of life, and it’s safe and doesn’t increase adverse reactions.
查看全文  查看/发表评论  下载PDF阅读器
关闭
关键词: 中国医药科学 中国医学 中国医学科学 中华医学 医学杂志 临床医学杂志 医学期刊 中国预防医学 中华预防医学 预防医学杂志 中国药学 药学杂志
药理杂志 中国中医 中医杂志 中华中医药 中医药杂志 中国医疗 医疗器械杂志 中国中西医结合 中国医药 医药杂志 医药期刊 医药论文 医学论文 科研论文 职称论文
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=E0F54BF06C7306DCA0DCBD97F46B191389D22DA4DFA464D7EE7FE7173EA5245B7266623F7E358EB36FD46C69E48E8656D556A8E25FAABEB466E3975066CAAD81B6EE7F05262EEB5EBB0ACF1108EC3DDEDC9BC212A7A84F8C46736A059A8CDC3AB1AF61601F9B3A23952D5FE4662EFFB8BCEBAF83BBA9D89F3046FFF7EA985E39558C641AEAF82A79&pcid=&cid=&jid=&yid=2A8D03AD8076A2E3&aid=&vid=&iid=F3583C8E78166B9E&sid=B91E8C6D6FE990DB&eid=DB817633AA4F79B9&fileno=20190992&flag=1&is_more=0">